Recombinant antigens rLipL21, rLoa22, rLipL32 and rLigACon4-8 for serological diagnosis of leptospirosis by enzyme-linked immunosorbent assays in dogs.
Authors: Ye Cuilian, Yan Weiwei, Xiang Hua, He Hongxuan, Yang Maosheng, Ijaz Muhammad, Useh Nicodemus, Hsieh Ching-Lin, McDonough Patrick L, McDonough Sean P, Mohamed Hussni, Yang Zhibang, Chang Yung-Fu
Journal: PloS one
Summary
# Editorial Summary: Recombinant Antigen ELISA for Canine Leptospirosis Diagnosis Leptospirosis remains a significant zoonotic concern globally, yet current diagnostic methods such as the microscopic agglutination test (MAT) are labour-intensive and require specialist laboratory facilities—limitations that prompted researchers to evaluate four recombinant Leptospira antigens (rLipL21, rLoa22, rLipL32 and rLigACon4-8) as alternatives for serological diagnosis in dogs. Testing 305 canine serum samples against five serovars (Pomona, Grippotyphosa, Icterohaemorrhagiae, Canicola and Hardjo), the researchers found that individual antigens achieved high sensitivity and specificity when compared to MAT, with rLipL21 showing the strongest individual performance (99.5% sensitivity, 84.3% specificity), whilst combined antigen panels improved diagnostic accuracy further—notably, rLoa22 and rLipL32 together achieved 94.1% specificity with 89.2% sensitivity. These recombinant antigen-based ELISAs offer practical advantages over traditional MAT approaches, being faster, more straightforward to perform, and amenable to standardisation across different laboratories, which could facilitate earlier diagnosis and treatment of leptospirosis in canine patients and support epidemiological surveillance efforts. Although the paper focuses on canine populations, the methodology and antigen selection may have relevance for practitioners working with horses, where leptospiral infection can cause abortion, renal disease and uveitis, though breed-specific validation would be essential before clinical adoption in equine practice.
Read the full abstract on PubMed
Practical Takeaways
- •This research demonstrates diagnostic methodology for leptospirosis in dogs using recombinant antigens, which is not directly applicable to equine practice
- •While the authors previously validated these same antigens for equine leptospirosis, this particular study focuses on canine serology and does not provide new information for equine practitioners
- •The ELISA approach using recombinant antigens offers an alternative to MAT testing that is easier to perform and interpret in laboratory settings
Key Findings
- •rLipL21 antigen achieved 99.5% sensitivity and 84.3% specificity for canine leptospirosis diagnosis by ELISA
- •Combined use of rLoa22 and rLipL32 antigens achieved 89.2% sensitivity and 94.1% specificity
- •All four recombinant antigens together provided both high sensitivity and specificity comparable to the standard MAT test
- •Individual antigen performance ranged from 89.7% to 99.5% sensitivity and 81.4% to 84.3% specificity against MAT